Moving Beyond Staging Alone in Melanoma: GEP Testing Refines Mortality Risk

Castle Biosciences’ DecisionDx-Melanoma test refines mortality risk within American Joint Committee on Cancer (AJCC) Cancer Staging System for patients with cutaneous melanoma, according to research presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.

DecisionDx-Melanoma is a gene expression profile (GEP) test that combines molecular insights with select clinicopathologic features.

“The findings being presented at AAD reinforce that staging alone does not tell the whole story,” says Harrison Nguyen MD, MBA, MPH, lead study author and Dermatologist and Mohs Micrographic Surgeon in Missouri City, TX, in a news release. “Incorporating DecisionDx-Melanoma into routine risk assessment provides physicians with biologic information that complements staging and supports more personalized management decisions, helping to identify patients who may warrant closer monitoring or earlier intervention, while also recognizing those who may be safely managed less intensively.”

In this analysis, registry data from 22 the Surveillance, Epidemiology, and End Results (SEER) sites were linked to data from patients with stage I–III cutaneous melanoma who were clinically tested with the DecisionDx-Melanoma test and had at least five years of follow-up or death from their disease. The test significantly stratified five-year melanoma-specific survival within T (tumor) categories and AJCC substages. In patients with T1 tumors, five-year melanoma-specific survival was 96.7% for those with low-risk (Class 1A) results vs. 70.0% for high-risk (Class 2B) results, and among patients with Stage IIB–III disease, melanoma-specific survival was 87.4% for low-risk vs. 48.5% for high-risk results.

Overall, the data show that DecisionDx-Melanoma can identify patients at higher or lower risk than predicted by AJCC staging alone, including high-risk T1 (thin) tumors with mortality risk approaching that of thicker melanomas, while also distinguishing lower-risk patients who may be appropriate for less intensive follow-up.